cholesteryl ester transfer protein

Featured Products

Cholesteryl Ester Transfer Protein, Monkey, ELISA Kit
Cholesteryl Ester Transfer Protein, Monkey, ELISA Kit by ARP American Research Products
Customer reviews
Product Description
Product Code:E09C0526Product:Cholesteryl Ester Transfer Protein, Monkey, ELISA KitSpecies:MonkeyELISA Method:Sandwich ELISADetection Range:0.5-10ng/mL, Sensitivity:0.1ng/mlSamples:Serum, plasma, cell culture supernatants, body fluid and tissue homogenateIntended Use:For Research Use Only
Product Description
There is overwhelming evidence that both elevated low-density lipoprotein (LDL) cholesterol and reduced high-density lipoprotein (HDL) cholesterol are independently associated with a substantially increased risk of developing premature atherosclerotic cardiovascular disease. Furthermore, the risk associated with low HDL cholesterol persists even when the level of LDL cholesterol has been reduced to levels below 70 mg/dL (1.8 mmol/L) by treatment with statins. This has led to a major research effort to discover therapies with the capacity to raise HDL cholesterol as effectively as statins lower LDL cholesterol. One logical approach is to find ways to shift the partitioning of cholesterol between LDLs and HDL towards the HDL fraction. Given that human plasma contains the cholesteryl ester transfer protein (CETP) that promotes the transfer of cholesterol from HDLs to LDLs, inhibition of this protein has the potential to shift the balance of plasma cholesterol in favour of the protective HDL fraction. The possibility that CETP may be pro-atherogenic by transferring cholesterol from the anti-atherogenic HDL fraction to pro-atherogenic particles in the very low-density lipoprotein (VLDL) and LDL fractions was first raised more than 15 years ago. This provided the rationale for a major research effort to test the possibility that inhibition of CETP may be anti-atherogenic. The updated version of this book documents the physiological functions of CETP, its possible contribution to the development of atherosclerosis and the evidence that its inhibition may translate into a protection against atherosclerosis.

Questions & answers

  1. Mamma Mia Mamma Mia says:
    How is cigarette smoke linked to essence disease?
    Lucia says:
    Cigarette Smoking Linked Pith Attacks In Early 50's For People With Common Gene Deviant. 14, 2008) — The. I read this information and found it was interesting ,please review this.
  1. Synageva BioPharma™ Joins the Supranational MPS Network in Support of MPS Awareness Day 2013
    Current onset LAL Deficiency, sometimes called Cholesteryl Ester Storage Affliction (CESD), is an underappreciated ... Synageva has several protein therapeutics in its dope development pipeline. Further information regarding Synageva BioPharma Corp ...
  2. New Clinical Pharmacology Work Findings Have Been Reported from Merck & Company
    A sedative interaction study for warfarin with a novel CETP inhibitor is expected to be useful in defining dosing regimens. WHAT THIS STUDY: ADDS This is the triumph study to show that there is no clinically meaningful pharmacokinetic interaction ...
  3. Sequencing of superagers offers medicament targets, but fewer than hoped
    one of the two big pharma firms with CETP inhibitors now in late-acting clinical development. Studies involving centenarians and nonagenerians have also linked outstanding variants of the human forkhead box O3A (FOXO3A) gene and the apolipoprotein ...

Will Cholesteryl Ester Transfer Protein Check Succeed Primarily

Myriad new drugs fail in the clinic because of efficacy, that is, the dose does not reduce risk for ASCVD. Developing new medicines to go into atherosclerotic cardiovascular disease (ASCVD), the paramount cause of death in the United States and in Europe, has not been more challenging ( 1 ). The number of new drug approvals is down, whereas the tariff of...

Google news feed

  1. Monthly Prescribing Reference Mediterranean Fast Improves Cholesterol Measures
    The researchers found that MedDiet-WL significantly reduced bare-low-density lipoprotein (VLDL)-apoCIII (−41.5%), cholesteryl ester transfer protein (-7%), and hepatic lipase concentrations (-7.1%). It also reduced the dimensions of small LDL (<255 Å;
  2. Merck In-Licenses from Xenon
    Merck's cardiovascular duct includes candidates like MK-0859, anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor which is being developed for cholesterol governance. Merck has started a large, event-driven cardiovascular clinical
2obd » Cholesteryl ester transfer protein - Orientations of Proteins ...
2obd » Cholesteryl ester transfer protein - Orientations of Proteins ...
Cholesteryl ester transfer protein - Stock Image C013/8895 - Science ...
Cholesteryl ester transfer protein - Stock Image C013/8895 - Science ...
Entity page for cholesteryl ester transfer protein
Entity page for cholesteryl ester transfer protein
... Of HDL Therapy?: HDL Metabolism & Cholesteryl Ester Transfer Protein
... Of HDL Therapy?: HDL Metabolism & Cholesteryl Ester Transfer Protein